Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Identifieur interne : 000937 ( Main/Exploration ); précédent : 000936; suivant : 000938Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Auteurs : Maria Papathanou [Pays-Bas] ; Rika Van Der Laan ; Peter Jenner ; Sarah Rose ; Andrew C. MccrearySource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- Adrenergic Agents (toxicity), Animals, Antiparkinson Agents (therapeutic use), Area Under Curve, Disease Models, Animal, Dyskinesias (drug therapy), Dyskinesias (etiology), Levodopa (administration & dosage), Male, Medial Forebrain Bundle (injuries), Oxidopamine (toxicity), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (etiology), Rats, Rats, Wistar, Time Factors.
- MESH :
- chemical , administration & dosage : Levodopa.
- chemical , therapeutic use : Antiparkinson Agents.
- chemical , toxicity : Adrenergic Agents, Oxidopamine.
- complications : Parkinson Disease.
- drug therapy : Dyskinesias, Parkinson Disease.
- etiology : Dyskinesias, Parkinson Disease.
- injuries : Medial Forebrain Bundle.
- Animals, Area Under Curve, Disease Models, Animal, Male, Rats, Rats, Wistar, Time Factors.
Abstract
The short duration of effect of levodopa is linked to pulsatile stimulation of striatal dopamine receptors and dyskinesia induction. However, the recent introduction of intraduodenal (i.d.) infusions and novel oral controlled release formulations of l-dopa may prevent dyskinesia induction and reduce the severity of established involuntary movements. We have compared the effects of twice-daily intraperitoneal (i.p.) administration and daily i.d. infusion of l-dopa on the induction and expression of abnormal involuntary movements in 6-hydroxydopamine (6-OHDA)-lesioned rats. Animals were treated with either twice-daily i.p. administration of l-dopa/carbidopa (7.85/12.5 mg/kg) or an 8-hour i.d. infusion of l-dopa/carbidopa (20/5 mg/mL; infusion rate: 0.04 mL/h) for 14 days, after which treatments were switched between groups and continued for a further 14 days. Pulsatile i.p. administration of l-dopa induced moderate to severe abnormal involuntary movements, which gradually increased in severity over the 14 days, but i.d. infusion of l-dopa induced abnormal involuntary movements of a similar severity. Switching from continuous i.d. to pulsatile i.p. administration of l-dopa continued to provoke severe abnormal involuntary movements expression. Switching from pulsatile i.p. to continuous i.d. l-dopa administration did not alter the peak abnormal involuntary movement severity but tended to reduce their duration. Treatment with less pulsatile l-dopa administration using i.d. infusion does not reduce the risk of the appearance of dyskinesia. By contrast, the duration of established dyskinesia can be reduced by more continuous l-dopa delivery in agreement with clinical experience.
DOI: 10.1002/mds.25218
PubMed: 23125107
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B78
- to stream PubMed, to step Curation: 000B78
- to stream PubMed, to step Checkpoint: 000951
- to stream Ncbi, to step Merge: 003884
- to stream Ncbi, to step Curation: 003884
- to stream Ncbi, to step Checkpoint: 003884
- to stream Main, to step Merge: 000937
- to stream Main, to step Curation: 000937
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.</title><author><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name><affiliation wicri:level="1"><nlm:affiliation>Abbott Healthcare Products B.V., Weesp, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Abbott Healthcare Products B.V., Weesp</wicri:regionArea><wicri:noRegion>Weesp</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Laan, Rika" sort="Van Der Laan, Rika" uniqKey="Van Der Laan R" first="Rika" last="Van Der Laan">Rika Van Der Laan</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C" last="Mccreary">Andrew C. Mccreary</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23125107</idno><idno type="pmid">23125107</idno><idno type="doi">10.1002/mds.25218</idno><idno type="wicri:Area/PubMed/Corpus">000B78</idno><idno type="wicri:Area/PubMed/Curation">000B78</idno><idno type="wicri:Area/PubMed/Checkpoint">000951</idno><idno type="wicri:Area/Ncbi/Merge">003884</idno><idno type="wicri:Area/Ncbi/Curation">003884</idno><idno type="wicri:Area/Ncbi/Checkpoint">003884</idno><idno type="wicri:Area/Main/Merge">000937</idno><idno type="wicri:Area/Main/Curation">000937</idno><idno type="wicri:Area/Main/Exploration">000937</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.</title><author><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name><affiliation wicri:level="1"><nlm:affiliation>Abbott Healthcare Products B.V., Weesp, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Abbott Healthcare Products B.V., Weesp</wicri:regionArea><wicri:noRegion>Weesp</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Laan, Rika" sort="Van Der Laan, Rika" uniqKey="Van Der Laan R" first="Rika" last="Van Der Laan">Rika Van Der Laan</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C" last="Mccreary">Andrew C. Mccreary</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents (toxicity)</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Area Under Curve</term><term>Disease Models, Animal</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (etiology)</term><term>Levodopa (administration & dosage)</term><term>Male</term><term>Medial Forebrain Bundle (injuries)</term><term>Oxidopamine (toxicity)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Rats</term><term>Rats, Wistar</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Adrenergic Agents</term><term>Oxidopamine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="injuries" xml:lang="en"><term>Medial Forebrain Bundle</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Area Under Curve</term><term>Disease Models, Animal</term><term>Male</term><term>Rats</term><term>Rats, Wistar</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The short duration of effect of levodopa is linked to pulsatile stimulation of striatal dopamine receptors and dyskinesia induction. However, the recent introduction of intraduodenal (i.d.) infusions and novel oral controlled release formulations of l-dopa may prevent dyskinesia induction and reduce the severity of established involuntary movements. We have compared the effects of twice-daily intraperitoneal (i.p.) administration and daily i.d. infusion of l-dopa on the induction and expression of abnormal involuntary movements in 6-hydroxydopamine (6-OHDA)-lesioned rats. Animals were treated with either twice-daily i.p. administration of l-dopa/carbidopa (7.85/12.5 mg/kg) or an 8-hour i.d. infusion of l-dopa/carbidopa (20/5 mg/mL; infusion rate: 0.04 mL/h) for 14 days, after which treatments were switched between groups and continued for a further 14 days. Pulsatile i.p. administration of l-dopa induced moderate to severe abnormal involuntary movements, which gradually increased in severity over the 14 days, but i.d. infusion of l-dopa induced abnormal involuntary movements of a similar severity. Switching from continuous i.d. to pulsatile i.p. administration of l-dopa continued to provoke severe abnormal involuntary movements expression. Switching from pulsatile i.p. to continuous i.d. l-dopa administration did not alter the peak abnormal involuntary movement severity but tended to reduce their duration. Treatment with less pulsatile l-dopa administration using i.d. infusion does not reduce the risk of the appearance of dyskinesia. By contrast, the duration of established dyskinesia can be reduced by more continuous l-dopa delivery in agreement with clinical experience.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C" last="Mccreary">Andrew C. Mccreary</name><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><name sortKey="Van Der Laan, Rika" sort="Van Der Laan, Rika" uniqKey="Van Der Laan R" first="Rika" last="Van Der Laan">Rika Van Der Laan</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000937 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000937 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23125107
|texte= Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23125107" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |